The pathogenesis and management of essential thrombocythaemia.
Green
A R
AR
University of Cambridge, Department of Haematology, MRC Centre, UK. arg1000@cam.ac.uk
D000208:Acute Disease; D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002999:Clone Cells / Q000473:pathology; D015870:Gene Expression; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000209:etiology; D008533:Megakaryocytes / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk; D013920:Thrombocythemia, Essential / Q000145:classification / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D019851:Thrombophilia / Q000209:etiology / Q000517:prevention & control
D000477:Alkylating Agents; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide; D001241:Aspirin; D006918:Hydroxyurea